Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group.

Autor:	McPherson S; Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. Electronic address: stuart.mcpherson2@nhs.net., Armstrong MJ; Liver Unit, Queen Elizabeth University Hospital Birmingham NHS Trust, Birmingham, UK; NIHR Biomedical Research Centre, University of Birmingham, Birmingham, UK., Cobbold JF; Oxford Liver Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; UK NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK., Corless L; Department of Gastroenterology, Hepatology and Endoscopy, Hull University Teaching Hospitals, Hull, UK., Anstee QM; Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK., Aspinall RJ; Portsmouth Liver Centre, Queen Alexandra Hospital, Portsmouth, UK., Barclay ST; Walton Liver Clinic, Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, UK., Brennan PN; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh BioQuarter, Edinburgh, UK., Cacciottolo TM; Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Wellcome Trust/MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK., Goldin RD; Division of Digestive Diseases, Imperial College, London, UK., Hallsworth K; Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK., Hebditch V; British Liver Trust, Bournemouth, UK., Jack K; Nottingham University Hospitals NHS Trust, Nottingham, UK., Jarvis H; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK; The Bellingham Practice, Northumberland, UK., Johnson J; Liver Unit, Queen Elizabeth University Hospital Birmingham NHS Trust, Birmingham, UK., Li W; Barts Liver Centre, Queen Mary University London and Barts Health NHS Trust, London, UK., Mansour D; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Queen Elizabeth Hospital, Gateshead NHS Foundation Trust, Gateshead, UK., McCallum M; Digestive Disorders Department, Aberdeen Royal Infirmary, Aberdeen, UK., Mukhopadhya A; Digestive Disorders Department, Aberdeen Royal Infirmary, Aberdeen, UK., Parker R; Leeds Liver Unit, St James's University Hospital Leeds, Leeds, UK., Ross V; Barts Liver Centre, Queen Mary University London and Barts Health NHS Trust, London, UK., Rowe IA; Leeds Institute for Medical Research, University of Leeds, Leeds, UK., Srivastava A; North Bristol Liver Unit, Southmead Hospital, North Bristol Trust, Bristol, UK., Thiagarajan P; Nottingham University Hospitals NHS Trust, Nottingham, UK., Thompson AI; Centre for Liver and Digestive Disorders, The Royal Infirmary, Edinburgh, Edinburgh, UK., Tomlinson J; Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK., Tsochatzis EA; UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK., Yeoman A; Gwent Liver Unit, The Grange University Health Board, Anuerin Bevan Health Board, Wales, UK., Alazawi W; Barts Liver Centre, Queen Mary University London and Barts Health NHS Trust, London, UK.
Jazyk:	angličtina
Zdroj:	The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2022 Aug; Vol. 7 (8), pp. 755-769. Date of Electronic Publication: 2022 Apr 28.
DOI:	10.1016/S2468-1253(22)00061-9
Abstrakt:	Non-alcoholic fatty liver disease (NAFLD) is common, affecting approximately 25% of the general population. The evidence base for the investigation and management of NAFLD is large and growing, but there is currently little practical guidance to support development of services and delivery of care. To address this, we produced a series of evidence-based quality standard recommendations for the management of NAFLD, with the aim of improving patient care. A multidisciplinary group of experts from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group produced the recommendations, which cover: management of people with, or at risk of, NAFLD before the gastroenterology or liver clinic; assessment and investigations in secondary care; and management in secondary care. The quality of evidence for each recommendation was evaluated by the Grading of Recommendation Assessment, Development and Evaluation tool. An anonymous modified Delphi voting process was conducted individually by each member of the group to assess the level of agreement with each statement. Statements were included when agreement was 80% or greater. From the final list of statements, a smaller number of auditable key performance indicators were selected to allow services to benchmark their practice. It is hoped that services will review their practice against our recommendations and key performance indicators and institute service development where needed to improve the care of patients with NAFLD. Competing Interests: Declaration of interests SM personal fees outside the submitted work from Gilead, Intercept, and Novo Nordisk. MJA has received fees for consultancy, advisory boards, and speaking from Novo Nordisk and Norgine. JFC has received fees for consultancy, advisory boards, and speaking from Intercept, Novo Nordisk, canNASH, and AstraZeneca. EAT has received fees for advisory boards and speaking from Falk Pharma, Intercept, Gilead, and Pfizer. AS has received fees for consultancy and speaking from Siemens. STB has received payment for advisory boards and speaking from AbbVie, Gilead, and Intercept. RJA has received honoraria for speaking and advisory board membership from Falk Pharma, Gilead, Intercept, Novartis, and Norgine. DM has received fees for consultancy from Intercept. PNB has received speaking and educational fees from Takeda. RP has received speaking fees and advisory board fees from Siemens, Norgine, Novo Nordisk, and Shionogi. AY has taken part in advisory boards and consultancy for Intercept and Novo Nordisk. HJ has received speaker fees from Intercept. WA has received fees for consultancy and lecturing from AstraZeneca, Janssen, Novo Nordisk, Gilead Science, Intercept, and Coherus and has received competitive grant funding from GSK and Gilead Science. LC has received personal fees outside the submitted work from Norgine, Intercept, and Novo Nordisk. JT has received personal fees outside the submitted work from Novartis and Poxel. QMA is coordinator of the IMI2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. He reports research grant funding from Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd, and Vertex, consultancy on behalf of Newcastle University for 89Bio, Allergan/Tobira, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company, Galmed, Genentech, Genfit, Gilead, Grunthal, HistoIndex, Indalo, Intercept, Inventiva, IQVIA, Janssen, Madrigal, MedImmune, Medpace, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd, Poxel, ProSciento, Raptor Pharma, Roche, Servier, Terns, The Medicines Company, and Viking Therapeutics, and speaker fees from Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, and MedScape. All other authors declared no competing interests. (Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu